Crystalline forms of Mnk inhibitors
US11952375B2 · kind B2 · utility
0Cited by
12References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 24, 2021 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Mar 13, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides crystalline solids of 6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione:The crystalline compounds of the present application are inhibitors of Mnk and finds utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.